News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Belzutifan-lenvatinib bests cabozantinib for RCC
11 Mar 2026
byAudrey Abella
A combination regimen comprising belzutifan and lenvatinib outdoes cabozantinib alone for the treatment of advanced clear cell renal cell carcinoma (ccRCC) in the phase III LITESPARK-011 study.
Belzutifan-lenvatinib bests cabozantinib for RCC
11 Mar 2026
PATINA: 1L palbociclib combo extends PFS in HR+, HER2+ mBC
11 Mar 2026
byKanas Chan
Addition of palbociclib to maintenance therapy yielded a median progression-free survival (mPFS) approaching 4 years, representing an effective first-line (1L) treatment for patients with hormone receptor–positive (HR+), HER2-positive (HER2+) metastatic breast cancer (mBC), according to the phase III PATINA trial.







